2160.T Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 09:15):

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally...

Stats
Dzisiejszy wolumen	938 100
Średni wolumen	1.05M
Kapitalizacja rynkowa	121.76B
EPS	¥0 ( 2024-02-13 )
Następna data zysków	( ¥0 ) 2024-05-14
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	14.75
ATR14	¥2.22 (0.09%)

Wolumen Korelacja

Długi: 0.02 (neutral)

Krótki: 0.83 (strong)

Signal:(55.298) Same movement expected

GNI Group Ltd. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

GNI Group Ltd. Korelacja - Waluta/Towar

-0.39
( neutral )

0.28
( neutral )

-0.73
( moderate negative )

0.47
( neutral )

0.07
( neutral )

GNI Group Ltd. Finanse

Annual	2023
Przychody:	¥26.01B
Zysk brutto:	¥22.43B (86.24 %)
EPS:	¥169.50

FY	2023
Przychody:	¥26.01B
Zysk brutto:	¥22.43B (86.24 %)
EPS:	¥169.50

FY	2022
Przychody:	¥17.42B
Zysk brutto:	¥14.74B (84.65 %)
EPS:	¥-18.29

FY	2021
Przychody:	¥12.69B
Zysk brutto:	¥11.09B (87.39 %)
EPS:	¥10.16

Financial Reports:

No articles found.

GNI Group Ltd.

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.